Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2024-11-11 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力2024年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2024 third extraordinary shareholders' meeting of the company. It includes details about the meeting date, attendance, voting results, and legal witness statements. The content focuses on the voting outcomes and procedural compliance rather than presenting a full report or financial statements. The document length is short (1679 characters) and it serves as an official announcement of voting results from a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-11-11 Chinese
天士力2024年第三次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled '2024 年第三次临时股东大会会议资料' which translates to '2024 Third Extraordinary General Meeting Materials'. It contains detailed agenda items, voting methods, attendance information, and a specific proposal regarding the 2024 third quarter profit distribution plan. The document includes procedural details about the meeting, voting, and legal opinions, but it is not a transcript of the meeting or the voting results themselves. It is a set of materials prepared for the shareholders to review before or during the meeting. The document length is 2759 characters, which is relatively short and consistent with meeting materials rather than a full report or transcript. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. Therefore, the document should be classified as AGM Information (AGM-R).
2024-11-01 Chinese
天士力关于公司获得美国FDA临床试验许可的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about receiving FDA clinical trial approval for a drug. It contains no financial data, no report or presentation, and is a regulatory announcement about a clinical trial permission. It is not an annual report, earnings release, or any financial filing. It is a regulatory announcement about a clinical trial approval, which fits best under Regulatory Filings (RNS). The document length is short and it is an announcement, not a report itself.
2024-10-29 Chinese
天士力2024年第三季度利润分配预案
Notice of Dividend Amount Classification · 95% confidence The document is a profit distribution plan for the third quarter of 2024 by TianShiLi Pharmaceutical Group Co., Ltd. It details the proposed cash dividend per share, total dividend amount, and the decision-making process including board and supervisory opinions. The document is an announcement of a dividend distribution plan, not the actual dividend payment notice or a full financial report. It is relatively short (1651 characters) and focuses on the dividend proposal and related procedural information. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2024-10-25 Chinese
天士力关于公司2024年前三季度主要经营数据的公告
Interim / Quarterly Report Classification · 95% confidence The document is titled as an announcement regarding the company's main operating data for the first three quarters of 2024. It contains detailed financial data such as revenue, cost, and gross margin segmented by industry, treatment area, product, and region for the period January to September 2024. The document explicitly states that the data is unaudited and is a disclosure of main operating data rather than a full financial report. The length is 2726 characters, which is relatively short and typical for a quarterly operating data announcement rather than a full interim report. There is no indication that this is a full interim report with comprehensive financial statements and analysis, nor is it a simple announcement of a report publication. Therefore, this document fits best as an Interim / Quarterly Report (IR) because it provides substantive financial data for a period shorter than a full fiscal year (the first three quarters). 9M 2024
2024-10-25 Chinese
天士力关于召开2024年第三次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2024 third extraordinary general meeting of shareholders for the company TianShiLi Pharmaceutical Group Co., Ltd. It includes details about the meeting date, voting methods, agenda items, and proxy forms. It does not contain financial statements or results but is an announcement related to a shareholders meeting. The document length is 2786 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2024-10-25 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.